<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Can J Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">2444</journal-id><journal-id journal-id-type="pmc-domain">canjpsych</journal-id><journal-id journal-id-type="publisher-id">CPA</journal-id><journal-title-group><journal-title>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</journal-title></journal-title-group><issn pub-type="ppub">0706-7437</issn><issn pub-type="epub">1497-0015</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10192829</article-id><article-id pub-id-type="pmcid-ver">PMC10192829.1</article-id><article-id pub-id-type="pmcaid">10192829</article-id><article-id pub-id-type="pmcaiid">10192829</article-id><article-id pub-id-type="pmid">35711159</article-id><article-id pub-id-type="doi">10.1177/07067437221099769</article-id><article-id pub-id-type="publisher-id">10.1177_07067437221099769</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder</article-title><trans-title-group xml:lang="fr"><trans-title>Rapport du groupe de travail du R&#233;seau canadien pour le traitement de l'humeur et de l'anxi&#233;t&#233; (CANMAT): une revue syst&#233;matique et des recommandations &#224; l&#8217;&#233;gard de l&#8217;utilisation du cannabis dans le trouble bipolaire et le trouble d&#233;pressif majeur</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2264-9586</contrib-id><name name-style="western"><surname>Tourjman</surname><given-names initials="SV">Smadar V.</given-names></name><degrees>MD, MSc, PhD</degrees><xref rid="aff1-07067437221099769" ref-type="aff">1</xref><xref rid="aff2-07067437221099769" ref-type="aff">2</xref><xref rid="corresp1-07067437221099769" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buck</surname><given-names initials="G">Gabriella</given-names></name><degrees>MSc</degrees><xref rid="aff3-07067437221099769" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jutras-Aswad</surname><given-names initials="D">Didier</given-names></name><degrees>MD, MSc</degrees><xref rid="aff1-07067437221099769" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khullar</surname><given-names initials="A">Atul</given-names></name><degrees>MD, MSc</degrees><xref rid="aff4-07067437221099769" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McInerney</surname><given-names initials="S">Shane</given-names></name><degrees>MB, MSc</degrees><xref rid="aff5-07067437221099769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saraf</surname><given-names initials="G">Gayatri</given-names></name><degrees>MD</degrees><xref rid="aff6-07067437221099769" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6990-6749</contrib-id><name name-style="western"><surname>Pinto</surname><given-names initials="JV">Jairo V.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff6-07067437221099769" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Potvin</surname><given-names initials="S">Stephane</given-names></name><degrees>PhD</degrees><xref rid="aff1-07067437221099769" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Poulin</surname><given-names initials="MJ">Marie-Jos&#233;e</given-names></name><degrees>MD</degrees><xref rid="aff7-07067437221099769" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frey</surname><given-names initials="BN">Benicio N.</given-names></name><degrees>MD, MSc, PhD</degrees><xref rid="aff8-07067437221099769" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kennedy</surname><given-names initials="SH">Sidney H.</given-names></name><degrees>MD</degrees><xref rid="aff5-07067437221099769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7142-4669</contrib-id><name name-style="western"><surname>Lam</surname><given-names initials="RW">Raymond W.</given-names></name><degrees>MD</degrees><xref rid="aff6-07067437221099769" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3352-6781</contrib-id><name name-style="western"><surname>MacQueen</surname><given-names initials="G">Glenda</given-names></name><degrees>MD, PhD</degrees><xref rid="aff9-07067437221099769" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Milev</surname><given-names initials="R">Roumen</given-names></name><degrees>MD, PhD</degrees><xref rid="aff10-07067437221099769" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parikh</surname><given-names initials="SV">Sagar V.</given-names></name><degrees>MD</degrees><xref rid="aff11-07067437221099769" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1655-2753</contrib-id><name name-style="western"><surname>Ravindran</surname><given-names initials="A">Arun</given-names></name><degrees>PhD</degrees><xref rid="aff5-07067437221099769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McIntyre</surname><given-names initials="RS">Roger S.</given-names></name><degrees>MD</degrees><xref rid="aff5-07067437221099769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schaffer</surname><given-names initials="A">Ayal</given-names></name><degrees>MD</degrees><xref rid="aff5-07067437221099769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="VH">Valerie H.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff9-07067437221099769" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Ameringen</surname><given-names initials="M">Michael</given-names></name><degrees>MD</degrees><xref rid="aff8-07067437221099769" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yatham</surname><given-names initials="LN">Lakshmi N.</given-names></name><degrees>MBBS, MBA</degrees><xref rid="aff6-07067437221099769" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6921-3870</contrib-id><name name-style="western"><surname>Beaulieu</surname><given-names initials="S">Serge</given-names></name><degrees>MD, PhD</degrees><xref rid="aff12-07067437221099769" ref-type="aff">12</xref></contrib></contrib-group><aff id="aff1-07067437221099769"><label>1</label>Department of Psychiatry and Addiction, Universit&#233; de Montr&#233;al, Montreal, Quebec, Canada</aff><aff id="aff2-07067437221099769"><label>2</label>Research Center, Institut Universitaire en Sant&#233; Mentale de Montr&#233;al, Montreal, Quebec, Canada</aff><aff id="aff3-07067437221099769"><label>3</label>Bipolar Disorders Clinic, <institution-wrap><institution-id institution-id-type="Ringgold">26632</institution-id><institution content-type="university">Douglas Mental Health University Institute</institution></institution-wrap>, Montreal, Quebec, Canada</aff><aff id="aff4-07067437221099769"><label>4</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">3158</institution-id><institution content-type="university">University of Alberta</institution></institution-wrap>, Edmonton, Alberta, Canada</aff><aff id="aff5-07067437221099769"><label>5</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, Ontario, Canada</aff><aff id="aff6-07067437221099769"><label>6</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">8166</institution-id><institution content-type="university">University of British Columbia</institution></institution-wrap>, Vancouver, British Columbia, Canada</aff><aff id="aff7-07067437221099769"><label>7</label><institution-wrap><institution-id institution-id-type="Ringgold">177450</institution-id><institution content-type="university">Institut Universitaire en Sant&#233; Mentale de Qu&#233;bec</institution></institution-wrap>, Qu&#233;bec, Canada</aff><aff id="aff8-07067437221099769"><label>8</label>Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada</aff><aff id="aff9-07067437221099769"><label>9</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">70401</institution-id><institution content-type="university">University of Calgary</institution></institution-wrap>, Calgary, Alberta, Canada</aff><aff id="aff10-07067437221099769"><label>10</label>&#8201;Department of Psychiatry, Queen&#8217;s University, Kingston, Ontario, Canada</aff><aff id="aff11-07067437221099769"><label>11</label>&#8201;Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA</aff><aff id="aff12-07067437221099769"><label>12</label>&#8201;Department of Psychiatry, McGill University, Montreal, Quebec, Canada</aff><author-notes><corresp id="corresp1-07067437221099769">Smadar V. Tourjman, Department of Psychiatry and Addiction, Universit&#233; de Montr&#233;al, 4701 Hochelaga Road, Montreal, QC H1N 3M5, Canada. 
Email: <email>vtourjman.iusmm@ssss.gouv.qc.ca</email></corresp><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Conferences and Advisory boards: Biron, Eisai, Elvium, Lundbeck, Janssen, Pfizer, Otsuka, Purdue, Sunovion; Research funding: DiaMentis, Pfizer, JanssenShares: Timeout Hydrate.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><volume>68</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">436054</issue-id><fpage>299</fpage><lpage>311</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-01 00:25:21.170"><day>01</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder content-type="sage">Canadian Psychiatric Association</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_07067437221099769.pdf"/><abstract><sec><title>Background</title><p>Given the increasing acceptability and legalization of cannabis in some jurisdictions, clinicians need to improve their understanding of the effect of cannabis use on mood disorders.</p></sec><sec><title>Objective</title><p>The purpose of this task force report is to examine the association between cannabis use and incidence, presentation, course and treatment of bipolar disorder and major depressive disorder, and the treatment of comorbid cannabis use disorder.</p></sec><sec><title>Methods</title><p>We conducted a systematic literature review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, Embase, PsycINFO, CINAHL and Cochrane Central Register of Controlled Trials from inception to October 2020 focusing on cannabis use and bipolar disorder or major depressive disorder, and treatment of comorbid cannabis use disorder. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to evaluate the quality of evidence and clinical considerations were integrated to generate Canadian Network for Mood and Anxiety Treatments recommendations.</p></sec><sec><title>Results</title><p>Of 12,691 publications, 56 met the criteria: 23 on bipolar disorder, 21 on major depressive disorder, 11 on both diagnoses and 1 on treatment of comorbid cannabis use disorder and major depressive disorder. Of 2,479,640 participants, 12,502 were comparison participants, 73,891 had bipolar disorder and 408,223 major depressive disorder without cannabis use. Of those with cannabis use, 2,761 had bipolar disorder and 5,044 major depressive disorder. The lifetime prevalence of cannabis use was 52%&#8211;71% and 6%&#8211;50% in bipolar disorder and major depressive disorder, respectively. Cannabis use was associated with worsening course and symptoms of both mood disorders, with more consistent associations in bipolar disorder than major depressive disorder: increased severity of depressive, manic and psychotic symptoms in bipolar disorder and depressive symptoms in major depressive disorder. Cannabis use was associated with increased suicidality and decreased functioning in both bipolar disorder and major depressive disorder. Treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.</p></sec><sec><title>Conclusion</title><p>The data indicate that cannabis use is associated with worsened course and functioning of bipolar disorder and major depressive disorder. Future studies should include more accurate determinations of type, amount and frequency of cannabis use and select comparison groups which allow to control for underlying common factors.</p></sec></abstract><trans-abstract xml:lang="fr"><title>Abr&#232;g&#232;</title><sec><title>Contexte</title><p>&#201;tant donn&#233; l&#8217;acceptabilit&#233; et la l&#233;galisation croissantes du cannabis dans certaines administrations, les cliniciens doivent am&#233;liorer leur compr&#233;hension de l&#8217;effet de l&#8217;utilisation du cannabis (UC) sur les troubles de l&#8217;humeur.</p></sec><sec><title>Objectif</title><p>Le rapport de ce groupe de travail vise &#224; examiner l&#8217;association entre l&#8217;UC et l&#8217;incidence, la pr&#233;sentation, le cours et le traitement du trouble bipolaire (TB) et du trouble d&#233;pressif majeur (TDM), et le traitement du trouble d&#8217;utilisation du cannabis (TUC) comorbide.</p></sec><sec><title>M&#233;thodes</title><p>Nous avons men&#233; une revue syst&#233;matique de la litt&#233;rature &#224; l&#8217;aide des lignes directrices PRISMA et avons cherch&#233; dans PUBMED, EMBASE, PsycINFO, CINAHL et le registre central Cochrane des essais contr&#244;l&#233;s du d&#233;but &#224; octobre 2020 en mettant l&#8217;accent sur l&#8217;UC et le TB ou le TDM, et le traitement du TUC comorbide. L&#8217;approche GRADE a servi &#224; &#233;valuer la qualit&#233; des donn&#233;es probantes et les consid&#233;rations cliniques ont &#233;t&#233; int&#233;gr&#233;es pour g&#233;n&#233;rer des recommandations CANMAT.</p></sec><sec><title>R&#233;sultats</title><p>Sur les 12 691 publications, 56 satisfaisaient aux crit&#232;res : 23 sur le TB, 21 sur le TDM, 11 sur les deux diagnostics, et une sur le traitement du TUC et du TDM comorbides. Sur les 2 479 640 participants, 12 502 &#233;taient des participants de comparaison, 73 891 souffraient du TB et 408 223 du TDM sans UC. Sur ceux ayant l&#8217;UC, 2 761 souffraient du TB et 5 044, du TDM. La pr&#233;valence de dur&#233;e de vie de l&#8217;UC &#233;tait de 52&#8211;71% et de 6&#8211;50% dans le TB et le TDM, respectivement. L&#8217;UC &#233;tait associ&#233;e &#224; un cours et &#224; des sympt&#244;mes aggrav&#233;s des deux troubles de l&#8217;humeur, les associations &#233;tant plus constantes dans le TB que dans le TDM : la gravit&#233; des sympt&#244;mes d&#233;pressifs, maniaques et psychotiques &#233;tait accrue dans le TB et les sympt&#244;mes d&#233;pressifs, dans le TDM. L&#8217;UC &#233;tait associ&#233;e &#224; une suicidabilit&#233; accrue et &#224; un fonctionnement diminu&#233; tant dans le TB que le TDM. Le traitement du TUC et du TDM <underline>comorbides n&#8217;a pas d&#233;montr&#233; de r&#233;sultats significatifs.</underline></p></sec><sec><title>Conclusion</title><p>Les donn&#233;es indiquent que l&#8217;UC est associ&#233;e avec un cours et un fonctionnement aggrav&#233;s du TB et du TDM. Les futures &#233;tudes devraient comprendre des d&#233;terminations plus pr&#233;cises du type, de la quantit&#233; et de la fr&#233;quence de l&#8217;UC et choisir des groupes de comparaison qui permettent de contr&#244;ler les facteurs communs sous-jacents.</p></sec></trans-abstract><kwd-group><kwd>Cannabis</kwd><kwd>Canadian Network for Mood and Anxiety Treatments</kwd><kwd>systematic reviews</kwd><kwd>bipolar disorder</kwd><kwd>major depressive disorder</kwd><kwd>substance use disorders</kwd><kwd>cannabinoids</kwd><kwd>comorbidity</kwd><kwd>GRADE</kwd><kwd>evidence-based medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>